Intended Purpose for SaMD.
22/3/2023
On 22nd March 2023, the UK Medicines and Healthcare Products Regulatory Agency – UK MHRA published a Guidance on defining the intended purpose for Software as a Medical Device (SaMD) to help SaMD manufacturers in meeting their statutory obligations. Here are some key points from the guidance:
their product to the “state of the art”, which includes creating documents to support this claim of safety. However, generating this safety documentation and defining “state of the art” can be complex and time-consuming.
The intended purpose statement should have a high level of clarity and specificity, which, if written adequately, should assist with several subsequent requirements of the regulations. The intended purpose statement should provide the reader with an understanding of the appropriate “state of the art”, product risk level, and the evidence required to demonstrate the safety of the product.
An inappropriate intended purpose statement can lead to non-compliance with the law and possible safety concerns. Our experts are helping digital health innovators to navigate regulatory requirements.
Apart from creating the right intended purpose statement, we are helping manufacturers bring their products successfully to the market.
Take your first step and get on the right side of the law by complying with #RegulatoryAffairs
Speak to our experts by sending an email at grs@globalregulatoryservices.com
Complete guidance can be found at - https://www.gov.uk/government/publications/crafting-an-intended-purpose-in-the-context-of-software-as-a-medical-device-samd
We are Driving innovation to market success™
